Factor VII for excessive bleeding following congenital heart disease surgery

• Published in: Asian cardiovascular & thoracic annals 2012-04, Vol.20 (2), p.120-125
• Main Authors: Changlani, Deepak Kishinchand, Devendaran, Vimalarani, Murmu, Udaya Charan, Ganesan, Selvakumar, Varghese, Roy, Kumar, Raghavannair Suresh
• Format: Article
• Language: English
• Subjects: Adolescent; Cardiac Surgical Procedures - adverse effects; Child; Child, Preschool; Dose-Response Relationship, Drug; Factor VIIa - administration & dosage; Factor VIIa - therapeutic use; Female; Heart Defects, Congenital - surgery; Humans; Incidence; India - epidemiology; Infant; Infant, Newborn; Male; Postoperative Hemorrhage - drug therapy; Postoperative Hemorrhage - epidemiology; Recombinant Proteins - administration & dosage; Recombinant Proteins - therapeutic use; Retrospective Studies; Survival Rate - trends; Young Adult
• ISSN: 0218-4923; 1816-5370
• DOI: 10.1177/0218492311433614

Recombinant activated factor VII may be effective in patients with severe bleeding following congenital heart disease surgery requiring cardiopulmonary bypass. From August 2009 through June 2011, 13 patients (median age, 5 months) were given recombinant activated factor VII for severe bleeding after open heart surgery, preventing sternal closure 2 h after completion of cardiopulmonary bypass, or chest tube drainage >10 mLċ kg−1ċh−1 for 2 h. The median dose was 75 µgċ kg−1. The response was positive if postoperative bleeding decreased, permitting sternal closure in the operating room, or if there was > 50% decrease in chest tube drainage. The 3 patients who received factor VIIa in the operating room had successful sternal closure within 1 h. Of the 10 patients who received factor VIIa in the intensive care unit, drainage decreased to